Idexx Laboratories (IDXX) Equity Average (2010 - 2026)

Idexx Laboratories (IDXX) has reported Equity Average for 17 consecutive years, with $1.6 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Equity Average rose 3.88% year-over-year to $1.6 billion; the TTM figure through Mar 2026 stood at $1.6 billion (up 3.88% YoY), while the FY2025 annual figure was $1.6 billion, up 3.92% from the prior year.
• Equity Average came in at $1.6 billion for Q1 2026 at Idexx Laboratories, roughly flat from $1.6 billion in the prior quarter.
• The five-year high for Equity Average was $1.6 billion in Q4 2024, with the low at $466.5 million in Q3 2022.
• Average Equity Average over 5 years is $1.2 billion, with a median of $1.5 billion recorded in 2025.
• Across the five-year window, Equity Average slumped 37.95% in 2022 and soared 156.46% in 2023, its largest moves.
• Year by year, Equity Average stood at $542.4 million in 2022, then jumped by 156.46% to $1.4 billion in 2023, then grew by 15.51% to $1.6 billion in 2024, then slipped by 1.46% to $1.6 billion in 2025, then slipped by 0.16% to $1.6 billion in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $1.6 billion, $1.6 billion, and $1.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.